GoAI
Get started
DexCom, Inc. logo

DexCom, Inc.

DXCM

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$92.34

+$2.12 · +2.35%

Aug 21, 4:00 PM ET

DXCM company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

88

Deep Value

Momentum

56

Neutral

Sentiment

66

Bullish

Risk resilience

60

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Jacob Steven Leach
Listed since
Apr 14, 2005
Employees
11,050

Market position

Day range

Current $92.34

52-week range

Current $92.34

Open
$89.605
Previous close
$90.22
Volume
3.48M
0.62× average
Average volume
5.6M
Average daily volume
Market cap
34.85B USD
Beta
1.41
Market reference 1
50-day average
$77.6284
+18.95% above average
200-day average
$69.3212
+33.21% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
26.37B USD
P/E (TTM)
35.65×
P/B (TTM)
13.52×
P/S (TTM)
7.01×
EV / EBITDA
19.41×
Earnings yield
3.23%
Free cash flow yield
4.16%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
62.47%
Operating margin
22.92%
Net margin
20.12%
Return on equity
30.46%
Return on assets
13.19%
Return on invested capital
16.61%

Financial health

Debt / equity
0.53×
Current ratio
1.88×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends75%51%27%3%Gross margin, FY2021: 68.63%Gross margin, FY2022: 64.72%Gross margin, FY2023: 63.19%Gross margin, FY2024: 60.46%Gross margin, FY2025: 60.10%Operating margin, FY2021: 10.86%Operating margin, FY2022: 13.44%Operating margin, FY2023: 16.50%Operating margin, FY2024: 14.88%Operating margin, FY2025: 19.56%Net margin, FY2021: 8.86%Net margin, FY2022: 11.73%Net margin, FY2023: 14.95%Net margin, FY2024: 14.29%Net margin, FY2025: 17.94%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 68.63%. Gross margin FY2022 64.72%. Gross margin FY2023 63.19%. Gross margin FY2024 60.46%. Gross margin FY2025 60.10%. Operating margin FY2021 10.86%. Operating margin FY2022 13.44%. Operating margin FY2023 16.50%. Operating margin FY2024 14.88%. Operating margin FY2025 19.56%. Net margin FY2021 8.86%. Net margin FY2022 11.73%. Net margin FY2023 14.95%. Net margin FY2024 14.29%. Net margin FY2025 17.94%.

Income trends

Revenue

4.66B USD+15.60%

Operating income

911.8M USD+51.97%

Net income

836.3M USD+45.14%
Income trends across reported periods5.11B USD3.33B USD1.55B USD−227.61M USDRevenue, FY2021: 2.45B USDRevenue, FY2022: 2.91B USDRevenue, FY2023: 3.62B USDRevenue, FY2024: 4.03B USDRevenue, FY2025: 4.66B USDOperating income, FY2021: 265.8M USDOperating income, FY2022: 391.2M USDOperating income, FY2023: 597.7M USDOperating income, FY2024: 600M USDOperating income, FY2025: 911.8M USDNet income, FY2021: 216.9M USDNet income, FY2022: 341.2M USDNet income, FY2023: 541.5M USDNet income, FY2024: 576.2M USDNet income, FY2025: 836.3M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.45B USD. Revenue FY2022 2.91B USD. Revenue FY2023 3.62B USD. Revenue FY2024 4.03B USD. Revenue FY2025 4.66B USD. Operating income FY2021 265.8M USD. Operating income FY2022 391.2M USD. Operating income FY2023 597.7M USD. Operating income FY2024 600M USD. Operating income FY2025 911.8M USD. Net income FY2021 216.9M USD. Net income FY2022 341.2M USD. Net income FY2023 541.5M USD. Net income FY2024 576.2M USD. Net income FY2025 836.3M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue4.66B USD4.03B USD3.62B USD2.91B USD2.45B USD
Cost of goods sold1.86B USD1.59B USD1.33B USD1.03B USD768M USD
Gross profit2.8B USD2.44B USD2.29B USD1.88B USD1.68B USD
Research and development599.1M USD552.4M USD505.8M USD484.2M USD604.2M USD
Selling, general, and administrative1.29B USD1.29B USD1.19B USD1.01B USD810.5M USD
Operating expenses1.89B USD1.84B USD1.69B USD1.49B USD1.41B USD
Interest income112.7M USD134.2M USD135M USD23.8M USD1.7M USD
Interest expense18.3M USD19M USD20.3M USD18.6M USD18.8M USD
Depreciation and amortization251.8M USD217.7M USD186M USD155.9M USD101.9M USD
Operating income911.8M USD600M USD597.7M USD391.2M USD265.8M USD
Net income836.3M USD576.2M USD541.5M USD341.2M USD216.9M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+8.42%
11 comparable reports
Latest EPS result
0.7
Estimate 0.61 · Beat by 14.57%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.740.590.430.28Q1 '25MissQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 13, 2025: actual 0.45, estimate 0.479, surprise -6.09%, Miss. Q2 2025, reported May 1, 2025: actual 0.32, estimate 0.327, surprise -2.20%, Miss. Q3 2025, reported Jul 30, 2025: actual 0.48, estimate 0.444, surprise +8.21%, Beat. Q4 2025, reported Oct 30, 2025: actual 0.61, estimate 0.576, surprise +5.90%, Beat. Q1 2026, reported Feb 12, 2026: actual 0.68, estimate 0.65, surprise +4.62%, Beat. Q2 2026, reported Apr 30, 2026: actual 0.56, estimate 0.466, surprise +20.27%, Beat. Q3 2026, reported Jul 30, 2026: actual 0.7, estimate 0.611, surprise +14.57%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 0.66, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates1.38B1.24B1.1B964.27MQ1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 13, 2025: actual 1.11B USD, estimate 1.11B USD, surprise +0.39%, Beat. Q2 2025, reported May 1, 2025: actual 1.04B USD, estimate 1.02B USD, surprise +1.83%, Beat. Q3 2025, reported Jul 30, 2025: actual 1.16B USD, estimate 1.12B USD, surprise +2.89%, Beat. Q4 2025, reported Oct 30, 2025: actual 1.21B USD, estimate 1.18B USD, surprise +2.16%, Beat. Q1 2026, reported Feb 12, 2026: actual 1.26B USD, estimate 1.25B USD, surprise +0.91%, Beat. Q2 2026, reported Apr 30, 2026: actual 1.19B USD, estimate 1.17B USD, surprise +1.47%, Beat. Q3 2026, reported Jul 30, 2026: actual 1.31B USD, estimate 1.29B USD, surprise +1.40%, Beat. Q4 2026, reported Oct 29, 2026: actual —, estimate 1.33B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$89.71

2.85% downside
Past 12 months12-month forecastHigh $105Average $89.71Low $64.00

Rating distribution

52 ratings
Strong buy12%
Buy4179%
Hold815%
Sell24%
Strong sell00%

Recent analyst actions

12 institutions

DXCM news

zacks.com

Here's Why DexCom (DXCM) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Read source
youtube.com

The Big 3: PH, DXCM, UNP

Dan Deming discusses why he sees sideways action in the stock market continuing through next week, noting anticipating for the Fed's Jackson Hole meeting. As for Thursday's Big 3, he sees an opportunity in…

Read source
defenseworld.net

Aurora Investment Counsel Invests $2.34 Million in DexCom, Inc. $DXCM

Aurora Investment Counsel bought a new stake in DexCom, Inc. (NASDAQ: DXCM) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 34,744 shares of the…

Read source
zacks.com

Here's Why DexCom (DXCM) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Read source
zacks.com

Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?

DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.

Read source
zacks.com

Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?

DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.

Read source

Corporate actions

Corporate action history

Stock split

Effective Jun 13, 2022

4:1

DXCM peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding DXCM

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
1.03B
Weight
0.04%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard S&P 500 ETF logoVanguard S&P 500 ETFVOO
Market value
845.41M
Weight
0.05%
AUM
1.7T USD
Expense ratio
0.03%
Price / 1D
$703.71+0.39%
Invesco QQQ Trust, Series 1 logoInvesco QQQ Trust, Series 1QQQ
Market value
749.48M
Weight
0.15%
AUM
485.41B USD
Expense ratio
0.18%
Price / 1D
$713.44+0.35%
Vanguard Morningstar Mid-Cap ETF logoVanguard Morningstar Mid-Cap ETFVO
Market value
696.9M
Weight
0.31%
AUM
224.7B USD
Expense ratio
0.03%
Price / 1D
$82.97+0.53%
iShares Core S&P 500 ETF logoiShares Core S&P 500 ETFIVV
Market value
469.75M
Weight
0.05%
AUM
891.84B USD
Expense ratio
0.03%
Price / 1D
$769.31+0.39%
State Street SPDR S&P 500 ETF logoState Street SPDR S&P 500 ETFSPY
Market value
431.54M
Weight
0.05%
AUM
817.87B USD
Expense ratio
0.09%
Price / 1D
$765.72+0.41%
Vanguard Morningstar Growth ETF logoVanguard Morningstar Growth ETFVUG
Market value
410.1M
Weight
0.11%
AUM
372B USD
Expense ratio
0.03%
Price / 1D
$87.50+0.38%
State Street Health Care Select Sector SPDR ETF logoState Street Health Care Select Sector SPDR ETFXLV
Market value
250.42M
Weight
0.56%
AUM
44.76B USD
Expense ratio
0.08%
Price / 1D
$174.62+1.29%

Continue in GoAI

Research DXCM

research.disclaimer